The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia
Open accessAbstract
In recent years, the metabotropic glutamate (mGlu) receptors have emerged as potential new drug targets for treatment of a range of CNS disorders. Some of the most compelling advances have been made in targeting specific mGlu receptor subtypes as a fundamentally new approach to the treatment of schizophrenia. Recent animal and clinical studies provide strong evidence that agonists of group II mGlu receptors (mGluR2 and mGluR3) are effective in the treatment of the positive symptoms of schizophrenia, and animal studies suggest that mGluR5 agonists could provide a novel approach for the treatment of all major symptom domains (positive, negative, and cognitive) of this disorder. Although the discovery of selective agonists of these receptors is a challenge, there have been recent advances in the discovery of highly selective positive allosteric modulators (PAMs) of mGluR2 and mGluR5. These mGlu receptor-selective PAMs have properties needed for optimization as clinical candidates and have robust effects in animal models that predict efficacy in treatment of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PHARMACOLOGY AND FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTORS
Conn, P. J., & Pin, J.-P. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.205 · Cited by 3,081
Self-citationMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Self-citationPatil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Lisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.005 · Cited by 1,010
Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
Lu, Y.-M., Jia, Z., Janus, C., Henderson, J. T., Gerlai, R., Wojtowicz, J. M., & Roder, J. C. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-13-05196.1997 · Cited by 634
Serotonin model of schizophrenia: emerging role of glutamate mechanisms
Aghajanian, G. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00046-6 · Cited by 529
Metabotropic Glutamate Receptors 1 and 5 Differentially Regulate CA1 Pyramidal Cell Function
Mannaioni, G., Marino, M. J., Valenti, O., Traynelis, S. F., & Conn, P. J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-16-05925.2001 · Cited by 441
Self-citationLorrain, D. S., Baccei, C. S., Bristow, L. J., Anderson, J. J., & Varney, M. A. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00652-8 · Cited by 432
Awad, H., Hubert, G. W., Smith, Y., Levey, A. I., & Conn, P. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-21-07871.2000 · Cited by 423
Self-citationCognitive Dysfunction in Schizophrenia: Convergence of γ-Aminobutyric Acid and Glutamate Alterations
Lewis, D. A., & Moghaddam, B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1372 · Cited by 404
Pisani, A., Gubellini, P., Bonsi, P., Conquet, F., Picconi, B., Centonze, D., Bernardi, G., & Calabresi, P. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00297-4 · Cited by 312
Kinney, G. G., O’Brien, J. A., Lemaire, W., Burno, M., Bickel, D. J., Clements, M. K., Chen, T.-B., Wisnoski, D. D., Lindsley, C. W., Tiller, P. R., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.079244 · Cited by 298
Self-citationMarek, G. J., Wright, R. A., Schoepp, D. D., Monn, J. A., & Aghajanian, G. K. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35262-0 · Cited by 280
Tan, H.-Y., Callicott, J. H., & Weinberger, D. R. (2007) · Cerebral Cortex · doi:10.1093/cercor/bhm069 · Cited by 266
Dopamine hypothesis of schizophrenia: Making sense of it all
Toda, M., & Abi-Dargham, A. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0041-7 · Cited by 235
Selective Abolition of the NMDA Component of Long-Term Potentiation in Mice Lacking mGluR5
Jia, Z., Lu, Y., Henderson, J., Taverna, F., Romano, C., Abramow-Newerly, W., Wojtowicz, J. M., & Roder, J. (1998) · Learning & Memory · doi:10.1101/lm.5.4.331 · Cited by 234
Kinney, G. G., Burno, M., Campbell, U. C., Hernandez, L. M., Rodriguez, D., Bristow, L. J., & Conn, P. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.048702 · Cited by 219
Self-citationA Family of Highly Selective Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5
O’Brien, J. A., Lemaire, W., Chen, T.-B., Chang, R. S. L., Jacobson, M. A., Ha, S. N., Lindsley, C. W., Schaffhauser, H. J., Sur, C., Pettibone, D. J., et al. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.3.731 · Cited by 209
Self-citationFell, M. J., Svensson, K. A., Johnson, B. G., & Schoepp, D. D. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.136861 · Cited by 204
Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems
Alagarsamy, S., Marino, M. J., Rouse, S. T., Gereau, R. W., Heinemann, S. F., & Conn, P. J. (1999) · Nature Neuroscience · doi:10.1038/6338 · Cited by 199
Self-citationThe Neurochemical Circuitry of Schizophrenia
Carlsson, A. (2006) · Pharmacopsychiatry · doi:10.1055/s-2006-931483 · Cited by 197
Neurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implications
Carlsson, A., Hansson, L. O., Waters, N., & Carlsson, M. L. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00228-2 · Cited by 187
Johnson, M. P., Baez, M., Jagdmann, G. E., Britton, T. C., Large, T. H., Callagaro, D. O., Tizzano, J. P., Monn, J. A., & Schoepp, D. D. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm034015u · Cited by 182
Galici, R., Echemendia, N. G., Rodriguez, A. L., & Conn, P. J. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.091074 · Cited by 175
Self-citationLindsley, C. W., Wisnoski, D. D., Leister, W. H., O'Brien, J. A., Lemaire, W., Williams, Burno, M., Sur, C., Kinney, G. G., Pettibone, D. J., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049400d · Cited by 170
Self-citationO’Brien, J. A., Lemaire, W., Wittmann, M., Jacobson, M. A., Ha, S. N., Wisnoski, D. D., Lindsley, C. W., Schaffhauser, H. J., Rowe, B., Sur, C., et al. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.061747 · Cited by 170
Self-citationGalici, R., Jones, C. K., Hemstapat, K., Nong, Y., Echemendia, N. G., Williams, L. C., de Paulis, T., & Conn, P. J. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.102046 · Cited by 169
Self-citationBenneyworth, M. A., Xiang, Z., Smith, R. L., Garcia, E. E., Conn, P. J., & Sanders‐Bush, E. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.035170 · Cited by 161
Self-citationSchaffhauser, H., Rowe, B. A., Morales, S., Chavez-Noriega, L. E., Yin, R., Jachec, C., Rao, S. P., Bain, G., Pinkerton, A. B., Vernier, J.-M., et al. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.4.798 · Cited by 160
Progress Towards Validating the NMDA Receptor Hypofunction Hypothesis of Schizophrenia
Lindsley, C. W., Shipe, W. D., Wolkenberg, S. E., Theberge, C. R., Williams, D., Jr., Sur, C., & Kinney, G. G. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777057599 · Cited by 156
Self-citationAssessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors
Brody, S. A., Dulawa, S. C., Conquet, F., & Geyer, M. A. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001404 · Cited by 153
Sharp, F. R., Tomitaka, M., Bernaudin, M., & Tomitaka, S. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01817-8 · Cited by 152
Attucci, S., Carla�, V., Mannaioni, G., & Moroni, F. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703904 · Cited by 150
Marino, M. J., & Conn, P. J. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007023339544 · Cited by 134
Self-citationde Paulis, T., Hemstapat, R., Chen, Y., Zhang, Y., Saleh, S., Alagille, D., Baldwin, R. M., Tamagnan, G. D., & Conn, P. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051252j · Cited by 133
Self-citationCampbell, U. C., Lalwani, K., Hernández, L. M., Kinney, G. G., Conn, P. J., & Bristow, L. J. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1827-5 · Cited by 126
Self-citationMa, B., Li, M., Nong, H., Shi, J.-G., Liu, G.-T., & Zhang, J.-J. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282feb0ac · Cited by 123
Rodriguez, A. L., Nong, Y., Sekaran, N. K., Alagille, D., Tamagnan, G. D., & Conn, P. J. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.016139 · Cited by 123
Self-citationUgolini, A., Corsi, M., & Bordi, F. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00095-7 · Cited by 113
Lecourtier, L., Homayoun, H., Tamagnan, G. D., & Moghaddam, B. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.003 · Cited by 104
NMDA-induced potentiation of mGluR5 is mediated by activation of protein phosphatase 2B/calcineurin
Alagarsamy, S., Saugstad, J. A., Warren, L., Mansuy, I. M., Gereau, R. W., & Conn, P. J. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.05.005 · Cited by 103
Self-citationZhang, Y., Rodriguez, A. L., & Conn, P. J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.090308 · Cited by 102
Self-citationPreclinical Pharmacology of mGlu2 / 3 Receptor Agonists: Novel Agents for Schizophrenia?
Schoepp, D. D., & Marek, G. J. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007024606177 · Cited by 100
Chen, Y., Goudet, C., Pin, J., & Conn, P. J. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.040097 · Cited by 99
Self-citationSpooren, W. P. J. M., Gasparini, F., van der Putten, H., Koller, M., Nakanishi, S., & Kuhn, R. R. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00269-7 · Cited by 94
Synapse structure: glutamate receptors connected by the shanks
Ehlers, M. D. (1999) · Current Biology · doi:10.1016/s0960-9822(00)80043-3 · Cited by 93
Chen, Y., Nong, Y., Goudet, C., Hemstapat, R., de Paulis, T., Pin, J., & Conn, P. J. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.032425 · Cited by 90
Self-citationLiu, J., & Moghaddam, B. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10607-1 · Cited by 88
Schizophrenia: Moving Beyond Monoamine Antagonists
Conn, P. J., Tamminga, C. A., Schoepp, D. D., & Lindsley, C. W. (2008) · Molecular Interventions · doi:10.1124/mi.8.2.7 · Cited by 84
Self-citationAyala, J. E., Niswender, C. M., Luo, Q., Banko, J. L., & Conn, P. J. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.12.009 · Cited by 82
Self-citationEthanol differentially affects ATP-gated P2X and P2X receptor subtypes expressed in oocytes
Davies, D. L., Kochegarov, A., Kuo, S. T., Kulkarni, A. A., WOODWARD, J., King, B. F., & Alkana, R. L. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.03.015 · Cited by 78
Doherty, A. J., Palmer, M. J., Bortolotto, Z. A., Hargreaves, A. C., Kingston, A. E., Ornstein, P. L., Schoepp, D. D., Lodge, D., & Collingridge, G. L. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703574 · Cited by 75
Meltzer, H. Y. (1999) · PubMed · Cited by 71
Challenges in the development of mGluR5 positive allosteric modulators: The discovery of CPPHA
Zhao, Z., Wisnoski, D. D., O’Brien, J. A., Lemaire, W., Williams, D. L., Jacobson, M. A., Wittman, M., Ha, S., Schaffhauser, H., Sur, C., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.11.081 · Cited by 71
Self-citationMeltzer, H. Y. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00255-3 · Cited by 55
Poisik, O. V., Raju, D. V., Verreault, M., Rodriguez, A. L., Abeniyi, O. A., Conn, P. J., & Smith, Y. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.03.006 · Cited by 53
Self-citationEvolution of schizophrenia drugs: a focus on dopaminergic systems.
Nikam, S. S., & Awasthi, A. K. (2008) · PubMed · Cited by 50
Pinkerton, A. B., Cube, R. V., Hutchinson, J. H., James, J. K., Gardner, M. F., Rowe, B. A., Schaffhauser, H., Rodriguez, D. E., Campbell, U. C., Daggett, L. P., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.01.077 · Cited by 49
Govek, S. P., Bonnefous, C., Hutchinson, J. H., Kamenecka, T. M., McQuiston, J., Pracitto, R., Zhao, L., Gardner, M. F., James, J. K., Daggett, L. P., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.06.017 · Cited by 43
Rowe, B. A., Schaffhauser, H., Morales, S., Lubbers, L. S., Bonnefous, C., Kamenecka, T. M., McQuiston, J., & Daggett, L. P. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.138271 · Cited by 40
Cube, R. V., Vernier, J., Hutchinson, J. H., Gardner, M. F., James, J. K., Rowe, B. A., Schaffhauser, H., Daggett, L. P., & Pinkerton, A. B. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.02.078 · Cited by 24
Chavez-Noriega, L. E., Marino, M. J., Schaffhauser, H., Campbell, U. C., & Conn, P. J. (2005) · Current Neuropharmacology · doi:10.2174/1570159052773369 · Cited by 21
Self-citation
Cited by
Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease
Niswender, C. M., & Conn, P. J. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.011008.145533 · Cited by 1,892
Self-citationMoghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Metabotropic glutamate receptors: From the workbench to the bedside
Nicoletti, F., Bockaert, J., Collingridge, G. L., Conn, P. J., Ferraguti, F., Schoepp, D. D., Wroblewski, J. T., & Pin, J. P. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.022 · Cited by 653
Self-citationHasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Kenakin, T., & Miller, L. J. (2010) · Pharmacological Reviews · doi:10.1124/pr.108.000992 · Cited by 573
Metadata
- Authors
- Conn, P. J., Lindsley, C. W., & Jones, C. K.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 30
- Issue
- 1
- Pages
- 25-31
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2065940220
- Cited by
- 330
- References
- 65
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.